A genome-wide association study in the U.K. Biobank reveals genetic factors influencing IgG serostatus against SARS-CoV-2, highlighting the role of HLA class II genes in variable immune responses to COVID-19 vaccines.
When KFF Health News published an article in August about the "prior authorization hell" Sally Nix said she went through to secure approval from her insurance company for the expensive monthly infusions she needs, we thought her story had a happy ending.
Researchers investigated the anticancer effects of drugs targeting human tumor-associated macrophages (TAMs) in vivo. In humanized murine models, they tested the effectiveness of an antibody to human signal regulatory protein alpha (SIRPĪ±) for cancer immunotherapy.
Study introduces a novel dry powder aerosol COVID-19 vaccine, showing its effectiveness in inducing strong immune responses and offering protection against various SARS-CoV-2 strains, including Omicron.
Hansa Biopharma today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid improvement in disease-related efficacy measures.